Navigation Links
Ibrutinib Monotherapy Clinical Trial Data in Patients with Waldenstrom's Macroglobulinemia Presented at the International Conference on Malignant Lymphoma in Lugano, Switzerland
Date:6/20/2013

lity and terms of any such financing, the safety and/or efficacy results of clinical trials of our product candidates, our failure to obtain regulatory approvals or comply with ongoing governmental regulation, our ability to commercialize, manufacture and achieve market acceptance of any of our product candidates, for which we rely heavily on collaboration with third parties, and our ability to protect and enforce our intellectual property rights and to operate without infringing upon the proprietary rights of third parties. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, performance or achievements and no assurance can be given that the actual results will be consistent with these forward-looking statements. For more information about the risks and uncertainties that may affect our results, please see the Risk Factors section of our filings with the Securities and Exchange Commission, including our transition report on Form 10-K for the six month period ended December 31, 2012 and quarterly reports on Form 10-Q. We do not intend to update any of the forward-looking statements after the date of this announcement to conform these statements to actual results, to changes in management's expectations or otherwise, except as may be required by law.

References

[1] Pub Med Health. Waldenstrom's macroglobulinemia; macroglobulinemia - primary; Lymphoplasmacytic lymphoma. Available from: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001614/. Accessed May 14, 2013.

[2] American Cancer Society. Waldenstrom macroglobulinema. Available from: http://www.cancer.org/acs/groups/cid/documents/webcontent/003148-pdf.pdf. Accessed May 14, 2013.

[3] Garcia-Sanz R, Ocio E. Novel treatment regimens for Waldenstrom's
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
2. Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
3. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
4. Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
5. Ibrutinib Expanded Access Program Open to Eligible U.S. Patients with Relapsed or Refractory Mantle Cell Lymphoma
6. Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
7. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
8. Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from U.S. Food and Drug Administration
9. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
10. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
11. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Aug. 28, 2015 ... the addition of the "Investigation Report on ... offering. Developed by Pharmacia & Upjohn ... agonist which effectively reduces intraocular pressure. As the ... (under the trade name of Xalatan) entered ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 Perrigo ... commented on the Mylan N.V. ("Mylan") (NASDAQ: MYL ... acquire Perrigo. "Our views of Mylan,s offer ... to be, based on our Board,s careful reflection of ... depend on the limited choices that Mylan has allowed ...
(Date:8/28/2015)... Aug. 28, 2015 , Joint ... Ra from Biostar , Published in ,Stem Cells ... of lifespan through multiple IV administration of Adipose-derived MSC ... life expectancy found , Commercialization within 5 years ... the possibility that adult mesenchymal stem cells (MSCs) may ...
Breaking Medicine Technology:China Latanoprost Market Investigation Report 2015-2019 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2
... Calif., Feb. 28, 2011 Sangamo BioSciences, Inc. (Nasdaq: ... positive preliminary clinical data from its Phase 1 trial ... HIV-infected subjects who are currently on highly active antiretroviral ... suboptimal CD4+ T-cell counts.  The study is designed to ...
... /PRNewswire/ -- Intuity Medical, Inc .™, ... announced that it has secured a $20M credit facility ... and Oxford Finance Corporation . The funds ... commercialize POGO™, a fully-integrated blood glucose monitoring system. ...
Cached Medicine Technology:Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections 2Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections 3Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections 4Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections 5Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections 6Intuity Medical Secures $20M Credit Facility From Silicon Valley Bank and Oxford Finance Corporation 2Intuity Medical Secures $20M Credit Facility From Silicon Valley Bank and Oxford Finance Corporation 3
(Date:8/28/2015)... ... August 28, 2015 , ... For Dallas, the time is nearing ... their subsidiary USPI Tenet Health. , The American Heart Association hosts their well-known Heart ... They believe that together, a difference can be made. Walkers can participate in the ...
(Date:8/28/2015)... ... , ... On May 30th, 2015, Best Drug Rehabilitation, a results-based substance abuse ... Mission” benefit concert in Mendon, IL. Held in the Show Barn at the Adams ... education programs in the underfunded local school districts of Mendon at neighboring Quincy, IL. ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... Device Library for documenting and diagramming network and data center assets and audio-video ... / Device Model, Cisco Nexus 5000 Series, HP ProLiant Gen9, EMC VNX Series ...
(Date:8/28/2015)... ... August 28, 2015 , ... CARF ... its adolescent residential, counseling, day treatment and intensive family based services. , By ... for quality and its pursuit of excellence. As a nonprofit charity for more ...
(Date:8/28/2015)... ... August 28, 2015 , ... Northridge dentists Dr. Elyson and ... just $199, patients can currently receive a one hour treatment of this teeth whitening ... it includes a number of unique features that can turn teeth up to nine ...
Breaking Medicine News(10 mins):Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 3Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2Health News:Northridge Dentists Dr. Elyson and Dr. Assili Now Offer a Special Promotion on Zoom Teeth Whitening 2
... ... and their families asked to share stories around men,s health issues , ... Minneapolis, Minnesota (PRWEB) June 15, 2009 -- In ... Scoop is calling on men and their family members to share their health-related experiences ...
... , CHICAGO, June 15 The following statement is attributable ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20081209/AMALOGO ) ... honored that President Obama will speak directly to physicians at ... to health reform this year that provides all Americans with ...
... announced today the first commercial, plant-based diamine oxidase (DAO). Dr. ... that this new diamine oxidase is orders of magnitude more ... is available as a lyophilized powder. Price will be $200 ... test assays to detect spoilage by the presence of histamines ...
... To Be Released Tuesday Show Employer Health Mandate Would Help ... , WASHINGTON, June 15 Hundreds of economists will ... nation,s health care system, and health care experts will release ... a conference call with reporters on Tuesday. , , ...
... delivery of gene therapy suppresses tumors in mice , ... able to fight lung cancer using gene therapy delivered by ... lung cancer that were treated with a vaporized viral vector ... than untreated mice. , Researchers also found that treated mice ...
... JOLLA, Calif., June 15 Transdel Pharmaceuticals, Inc. (OTC ... developing non-invasive, topically administered products, announced that they anticipate ... of Ketotransdel(R) during the third quarter of 2009. ... of a randomized, double-blind, placebo controlled trial to evaluate ...
Cached Medicine News:Health News:Tough Guys Speak Out About Men's Health On The Healthcare Scoop 2Health News:Tough Guys Speak Out About Men's Health On The Healthcare Scoop 3Health News:AMA Committed to Health Reform, Welcomes President Obama 2Health News:Coming Soon: Lung-Cancer Spray? 2Health News:Transdel Pharmaceuticals Provides Update on Timing of Results for Phase 3 Study 2Health News:Transdel Pharmaceuticals Provides Update on Timing of Results for Phase 3 Study 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... MacularProtect delivers levels of nutrients ... and macular health in the ... The National Eye Institute. MacularProtect ... lutein, an antioxidant found to ...
Oculair (re-formulated Syntrx Complete) is a potent full-spectrum multiple vitamin/mineral/antioxidant dietary supplement that supports the normal aging process. It is designed to reflect the most re...
Medicine Products: